J Tissue Eng Regen Med. 2016 Nov 18. doi: 10.1002/term.2254
The use of multipotent mesenchymal stromal cells (MSCs) as candidate medicines for treating a variety of pathologies is based on their qualities as either progenitors for the regeneration of damaged tissue or producers of a number of molecules with pharmacological properties. The osteogenic potential of MSCs derived following this methodology was further evaluated in vivo in a translational model of osteonecrosis of the femoral head, in which the persistence of grafted cells in the host tissue and their lineage commitment into osteoblasts and osteocytes was demonstrated by tracking enhanced green fluorescent protein-labelled cells.
Autor: Caminal M, Vélez R, Rabanal RM, Vivas D, Batlle-Morera L, Aguirre M, Barquinero J, García J, Vives J